August 18, 2021
2 min watch
Save
VIDEO: ILCC crossfire panel addresses frontline immunotherapy in advanced NCSLC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
David R. Gandara, MD, summarized a crossfire panel from the International Lung Cancer Congress where experts discussed use of immunotherapy-containing regimens in the frontline setting for patients with advanced-stage non-small cell lung cancer.
“They all gave excellent presentations, pro and con, and in some instances, they agreed,” Gandara, director of the thoracic oncology program at UC Davis Comprehensive Cancer Center and chief medical officer for the International Society of Liquid Biopsy, told Healio.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Gandara reports receiving institutional research grants from Amgen, AstraZeneca, Genentech and Merck; and serving as a consultant or on advisory boards for AstraZeneca (institutional), Roche-Genentech (institutional), Guardant Health (institutional), Inivata, IO Biotech (institutional), Lilly, Merck, Novartis and Oncocyte (institutional)
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.